最 低 价：￥754.70
定 价：￥1161.00
作 者：Elliott M. Antman 著 著
出 版 社：Oversea Publishing House
出版时间：2006-12-1
I S B N：9781416033585
| "This multi-author book contains comprehensive information on cardiovascular therapeutics, a rapidly changing field. Dr Antman is to be congratulated for bringing together 112 experts in their respective fields who collectively contribute 55 chapters. All aspects of cardiovascular therapeutics are covered." Circulation |
| Color Plates follow page xxiv. SECTION 1 Decision-Making and Therapeutic Strategies in Cardiovascular Medicine 1. Tools for Assessment of Cardiovascular Tests and Therapies Elliott M. Antman, Robert M. Califf, and Joel Kupersmith Interpretation of Diagnostic Tests Clinical Trials How to Read and Interpret a Clinical Trial Meta-Analysis Cost-Effectiveness Analysis 2. The Use of Cardiovascular Drugs: Pharmacological Principles, 35 Stanley Nattel Pharmacokinetic Factors Oral Bioavailability (F) Volume of Distribution Protein Binding Elimination and t1/2 Pharmacodynamic Factors Dose Drug Interactions Pharmacogenomics 3. Gene Therapies and Stem Cell Therapies Gene Therapies for Cardiovascular Diseases: Where We Are and Where We Are Going Luis G. Melo, Christopher A. Ward, and Victor J. Dzau Overview Gene Therapies for Myocardial Protection Gene Therapies for Myocardial Rescue Gene Therapies for Vascular Protection Clinical Gene Therapy Perspectives and Future Directions Stem Cell Therapy for Cardiovascular Disorders Kai C. Wollert and Helmut Drexler Potential Donor Cells Modes of Cell Delivery Clinical Application of Stem Cell Therapy Coronary Artery Disease with No Mechanical Revascularization Option Ischemic Cardiomyopathy, Chronic Heart Failure The Foreseeable Future of Cardiovascular Stem Cell Therapy 4. The Process of Regulatory Review for New Cardiovascular Devices Neal L Muni and Brain D. Zuckerman Regulatory History of the Device Review Process The Temple Report and Evolution of the Device Regulatory Process Risk, Benefit, and the Product Life Cycle Ensuring the Safety of Marketed Devices Conclusion SECTION 2 Ischemic Heart Disease 5. Pharmacologic Options for Treatment of Ischemic Disease Jonathan Abrams, John Schroeder, William 14. Frishman, and lane Freedman The Organic Nitrates Calcium Channel Blockers β-Adrenergic Blockers Thrombosis and Ischemic Cardiovascular Disease Thrombosis: Future Directions 6. Mechanical Approaches to Percutaneous Coronary Intervention Jahuna Karha, A. Michael Lincoff, and Stephen G. Ellis Coronary Angioplasty Other Devices Intravascular Imaging Techniques Summary 7. Treatment with Drug-Eluting Stents George D. Dangas Drug-Eluting Stent System Results of Main Clinical Trials of Approved DES Clinical Use of DES in Different Patient and Clinical Subsets In-Stent Restenosis DES Thrombosis Adjunctive Pharmacologic Therapy Future Directions 8. Revascularization Options for Ischemic Heart Disease: Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention Oon C. Ooi, Charles J. Mullany, and Charanjit S. Rihal Effectiveness of Revascularization: CABG Effectiveness of Revascularization: PCI Relative Benefits of PCI and CABG …… SECTION 3 heart Failure SECTION 4 Arrhythmias/Conduction Disturbances SECTION 5 Dyslipoproteinemias/Atherosclerosis SECTION 6 Hypertension SECTION 7 Other Cardiovascular Conditions APPENDIX 1 APPENDIX 2 APPENDIX 3 |
内容加载中，请稍后...
商品评论（0条）